Banque Pictet & Cie SA raises DexCom holdings by 58.2% in fourth-quarter 13F filing

Banque Pictet & Cie SA increased its stake in DexCom, Inc. by 58.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund held 109,823 shares of DexCom after purchasing an additional 40,411 shares in the quarter. Its DexCom holdings were valued at 7,289,000 USD at the end of the most recent quarter.

Institutional activity around DexCom

Other institutional investors also reported changes to their positions in DexCom. CVA Family Office LLC increased its stake by 48.5% in the fourth quarter, bringing its total to 450 shares valued at 30,000 USD after purchasing an additional 147 shares. GAMMA Investing LLC raised its holdings by 2.5% in the third quarter to 7,043 shares worth 474,000 USD, following an additional purchase of 169 shares. IFP Advisors Inc boosted its position by 24.7% in the third quarter to 900 shares valued at 61,000 USD after buying an additional 178 shares.

Inspire Investing LLC grew its DexCom holdings by 6.1% in the third quarter to 3,139 shares valued at 211,000 USD, after purchasing an additional 180 shares. Personal CFO Solutions LLC increased its stake by 5.0% in the third quarter to 3,864 shares valued at 260,000 USD, following an additional purchase of 185 shares. Overall, 97.75% of the stock is owned by institutional investors and hedge funds.

Insider transactions

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock on Monday, March 16. The shares were sold at an average price of 64.85 USD, for total proceeds of 110,245.00 USD. After the transaction, the executive vice president directly owned 112,904 shares, valued at 7,321,824.40 USD. The sale represented a 1.48% decrease in his ownership stake. Company insiders own 0.32% of the company’s stock.

Wall Street outlook and consensus targets

Analysts have issued a range of views on DexCom. Robert W. Baird set an 87.00 USD price objective in a research note dated Friday, February 13. Barclays restated an underweight rating and set a 72.00 USD price target (up from 71.00) in a report dated Friday, February 13. Morgan Stanley reaffirmed an overweight rating on Monday, January 12. Piper Sandler reiterated an overweight rating on Thursday, February 5. BTIG Research reiterated a buy rating and issued an 85.00 USD price objective on Monday, March 9.

Two analysts rated the stock Strong Buy, eighteen rated it Buy, three assigned a Hold rating, and one gave a Sell rating. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of 86.50.

Market performance and financial results

DexCom shares opened at 62.22 USD on Friday. The stock’s 50-day moving average was 69.32, while the 200-day moving average was 67.30. The company reported a current ratio of 1.88, a quick ratio of 1.59, and a debt-to-equity ratio of 0.45. DexCom’s 1-year range was 54.11 USD to 89.98 USD, and the company’s market capitalization was 23.95 billion USD. Valuation metrics included a P/E ratio of 29.63, a PEG ratio of 1.22, and a beta of 1.55.

DexCom last reported quarterly earnings on Thursday, February 12. The company posted 0.68 EPS for the quarter, exceeding analysts’ consensus estimate of 0.65 by 0.03. Revenue was 1.26 billion USD, compared with a consensus estimate of 1.25 billion. DexCom reported a net margin of 17.94% and a return on equity of 32.12%. Quarterly revenue increased 13.1% year over year. In the prior year period, the company posted 0.45 EPS. Analysts expect DexCom to report 2.03 EPS for the current fiscal year.

Company profile

DexCom, Inc. develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products provide near real-time glucose readings, trend information, and alerts to support insulin dosing decisions and help reduce hypoglycemia and hyperglycemia. The company’s offerings include wearable glucose sensors, wireless transmitters, and software applications that deliver data to smartphones, dedicated receivers, and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom focuses on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.